Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9375474 | 1.00 | TSHR (0.52) | TSHRCHRM2CHRM1MEN1CYP2D6 | |
| SCHEMBL22869234 | 1.00 | TSHR (0.52) | TSHRCHRM2CHRM1MEN1CYP2D6 | |
| SCHEMBL19365113 | 0.90 | TSHR (0.48) | TSHRCHRM2CHRM1MEN1CYP2D6 | |
| SCHEMBL7921047 | 0.86 | TSHR (0.55) | TSHRCHRM2CHRM1MEN1CYP2D6 | |
| SCHEMBL14765414 | 0.86 | TSHR (0.55) | TSHRCHRM2CHRM1MEN1CYP2D6 | |
| SCHEMBL24601306 | 0.83 | TSHR (0.43) | TSHRCHRM2CHRM1MEN1CYP2D6 | |
| SCHEMBL13296959 | 0.81 | TSHR (0.46) | TSHRCHRM2CHRM1MEN1CYP2D6 | |
| SCHEMBL24313653 | 0.81 | TSHR (0.42) | TSHRCHRM2CHRM1MEN1CYP2D6 | |
| SCHEMBL17831609 | 0.81 | TSHR (0.42) | TSHRCHRM2CHRM1MEN1CYP2D6 | |
| SCHEMBL25979999 | 0.81 | TSHR (0.42) | TSHRCHRM2CHRM1MEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066379-B2 | Gracilin A and congeners as immunosuppressive and neuroprotective agents | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210002245-A1 | GRACILIN A AND CONGENERS AS IMMUNOSUPPRESSIVE AND NEUROPROTECTIVE AGENTS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002245-A1 | GRACILIN A AND CONGENERS AS IMMUNOSUPPRESSIVE AND NEUROPROTECTIVE AGENTS | GRIN2A, GRIN3B, GRIN1 | TSHR 2457/4885CHRM2 3367/4885CHRM1 3823/4885 |
| US-11066379-B2 | Gracilin A and congeners as immunosuppressive and neuroprotective agents | GRIN2A, GRIN3B, GRIN1 | TSHR 2457/4885CHRM2 3367/4885CHRM1 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.